ADMA Biologics, Inc. (ADMA) SEC Filings & Earnings Calls

Pricing pressure in U.S. immune globulin market could impact margins.

“FY2026 outlook continues to reflect sustained competitive dynamics and pricing pressure within the U.S. immune globulin market.” · word for word

Customer concentration

“For the three and six months ended June 30, 2026, three customers represented an aggregate of approximately 76% and 79%, respectively, of the Company’s consolidated revenues.” · word for word

Securities class action lawsuit

“On July 10, 2026, plaintiff Lisa Mazzarino filed a putative securities class action lawsuit... against the Company... alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.”

Debt covenant compliance

“The JPM Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions... including a maximum total leverage ratio of 2.50 to 1.00 and a minimum fixed charge coverage ratio of 1.20 to 1.00.” · word for word

Increased competitive dynamics in U.S. plasma-derived therapies and IG market; BIVIGAM revenue down 54%.

“the market for U.S. plasma derived therapies (PDT) and immunoglobulin (IG) experienced increased competitive dynamics” · word for word

Guidance lowered and long-term guidance withdrawn due to competitive pressures.

“Withdrawing previously provided long-term guidance due to current competitive dynamics” · word for word

Distributor inventory behavior causing near-term topline pressure.

“variability in distributor ordering patterns, created near-term topline pressures” · word for word

Customer concentration

“two customers accounted for an aggregate of approximately 82% of the Company's total accounts receivable” · word for word

Product concentration

“ASCENIV revenue $97.5M vs BIVIGAM $15.4M - heavy reliance on ASCENIV”

Debt covenant compliance

“maximum total leverage ratio of 2.50 to 1.00 and a minimum fixed charge coverage ratio of 1.20 to 1.00” · word for word

Customer Concentration

“For the year ended December 31, 2025, two customers, BioCare, Inc. ('BioCare') and Priority Healthcare Distribution, Inc. ('CuraScript'), represented an aggregate of approximately 73% of our consolidated revenues.” · word for word

Competition from Larger Players

“We face, and will continue to face, intense competition from both U.S.-based and foreign producers of plasma products, some of which have lower cost structures, greater access to capital, greater resources for research and development, and more sophisticated marketing capabilities.”

Dependence on Third-Party Plasma Supply

“Our procurement of RSV plasma primarily from third parties reflects a deliberate shift toward a more flexible, capital-efficient supply model which is expected to deliver accretive cost savings beginning in fiscal year 2026”

Regulatory and Manufacturing Complexity

“The biologics manufacturing process is time consuming and complex. The time for collection, manufacturing and release of a batch of IG is estimated at 7 to 12 months”

Short seller allegations could damage investor confidence and lead to increased scrutiny of inventory and channel practices.

“Short seller Culper Research issued a report on March 24, 2026 alleging channel stuffing and misrepresentation of ASCENIV's competitive position.”

Share repurchase funded by debt increases financial leverage.

“funded with borrowings under its existing $225 million revolving credit facility”

Customer concentration

“For the year ended December 31, 2025, two customers, BioCare, Inc. and Priority Healthcare Distribution, Inc., represented an aggregate of approximately 73% of our consolidated revenues.” · word for word

Dependence on third-party plasma supply agreements

“We have entered into long-term plasma supply agreements with the purchaser of our three centers... Our procurement of RSV plasma primarily from third parties reflects a deliberate shift toward a more flexible, capital-efficient supply model” · word for word

Competition from larger plasma product manufacturers

“The plasma products industry is highly competitive. We face, and will continue to face, intense competition from both U.S.-based and foreign producers of plasma products, some of which have lower cost structures, greater access to capital, greater resources for research and development, and more sophisticated marketing capabilities.” · word for word

CFO transition could cause short-term disruption, but consulting period ensures continuity.

“Brad Tade retiring as CFO; Terry Kohler appointed; Mr. Tade will serve in a consulting capacity through July 2026.”

Customer concentration

“Three customers accounted for an aggregate of approximately 91% of the Company's total accounts receivable.” · word for word

Dependence on RSV plasma supply agreements

“Grifols supplies a minimum of 35,000 liters of RSV plasma annually; KEDPlasma supplies a minimum of 35,000 liters of RSV plasma annually.”

Temporary competitive dynamics in standard IVIG markets impacting BIVIGAM.

“temporary competitive dynamics in standard IVIG markets, mainly impacting BIVIGAM” · word for word

Higher effective tax rate impacting net income.

“Year-over-year net income growth was tempered by a higher effective tax rate” · word for word